NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat

Experimental Neurology

Volumn 271, Issue , 2015, Pages 335-350

  Iderberg, H ^a   McCreary, A C ^b   Varney, M A ^c   Kleven, M S ^d,e   Koek, W ^d,f   Bardin, L ^d   Depoortere R ^d   Cenci, M A ^a   Newman Tancredi, A ^c  

^a LUND UNIVERSITY   (Sweden)

^b CHARLES RIVER LABORATORIES   (United States)

^c NEUROLIXIS INC   (United States)

^d Centre d'Immunologie Pierre Fabre   (France)

^e Biopharma R and D Consulting   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

5 HT1A agonist; 5 HT1A receptor; Befiradol; L DOPA induced dyskinesia; Mood deficits; NLX 112; Parkinson's disease

Indexed keywords

BEFIRADOL; DOPAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIPARKINSON AGENT; HALOPERIDOL; LEVODOPA; OXIDOPAMINE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 AGONIST;

AKINESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY POSTURE; BRAIN DAMAGE; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; DYSKINESIA; FEMALE; FORCED SWIM TEST; IMMOBILITY; LEVODOPA-INDUCED DYSKINESIA; MALE; NEUROCHEMISTRY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; ROTAROD TEST; SEROTONINERGIC SYSTEM; TASK PERFORMANCE; ANIMAL; BRAIN; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; DRUG INTERACTION; DYSKINESIA, DRUG-INDUCED; METABOLISM; MOVEMENT (PHYSIOLOGY); PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; SEROTONIN SYNDROME; SPRAGUE DAWLEY RAT; SWIMMING; VOCALIZATION;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CATALEPSY; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; LEVODOPA; MOVEMENT; NEUROTRANSMITTER AGENTS; OXIDOPAMINE; PIPERIDINES; PSYCHOMOTOR PERFORMANCE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN SYNDROME; SWIMMING; VOCALIZATION, ANIMAL;

EID: 84936853380     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.05.021     Document Type: Article

References (76)

1. Antonelli T., Fuxe K., Tomasini M.C., Bartoszyk G.D., Seyfried C.A., Tanganelli S., Ferraro L. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005, 58:193-199.
2. Assie M.B., Bardin L., Auclair A.L., Carilla-Durand E., Depoortere R., Koek W., Kleven M.S., Colpaert F., Vacher B., Newman-Tancredi A. F15599, a highly selective post-synaptic 5-HT1A receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. Int. J. Neuropsychopharmacol. 2010, 13:1285-1298.
3. 1A receptor-mediated, behaviorally specific analgesia. Eur. J. Pharmacol. 2001, 421:109-114.
4. Bardin L., Gregoire S., Aliaga M., Malfetes N., Vitton O., Ladure P., Newman-Tancredi A., Depoortere R. Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. Neurosci. Res. 2010, 66:135-140.
5. Bargiotas P., Konitsiotis S. Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments. Neuropsychiatr. Dis. Treat. 2013, 9:1605-1617.
6. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Bjorklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov. Disord. 2013, 28:1088-1096.
7. Bill D.J., Knight M., Forster E.A., Fletcher A. Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. Br. J. Pharmacol. 1991, 103:1857-1864.
8. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 1994, 17:73-82.
9. Breger L.S., Dunnett S.B., Lane E.L. Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat. Neurobiol. Dis. 2013, 50:142-150.
10. Bruins Slot L.A., De Vries L., Newman-Tancredi A., Cussac D. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur. J. Pharmacol. 2006, 534:63-70.
11. Bruins Slot L.A., Koek W., Tarayre J.P., Colpaert F.C. Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640. Eur. J. Pharmacol. 2003, 466:271-279.
12. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in Parkinsonian rats. Brain J. Neurol. 2007, 130:1819-1833.
13. Carta M., Carlsson T., Munoz A., Kirik D., Bjorklund A. Involvement of the serotonin system in l-DOPA-induced dyskinesias. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S154-S158.
14. Celada P., Bortolozzi A., Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 2013, 27:703-716.
15. Cenci A.M. Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front. Neurol. 2014, 5.
16. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
17. Cenci M.A., Ohlin K.E., Odin P. Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol. Disord. Drug Targets 2011, 10:670-684.
18. Colpaert F.C. 5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr. Opin. Investig. Drugs 2006, 7:40-47.
19. Colpaert F.C., Tarayre J.P., Koek W., Pauwels P.J., Bardin L., Xu X.J., Wiesenfeld-Hallin Z., Cosi C., Carilla-Durand E., Assie M.B., Vacher B. Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. Neuropharmacology 2002, 43:945-958.
20. Dekeyne A., Brocco M., Adhumeau A., Gobert A., Millan M.J. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents. Psychopharmacology 2000, 152:55-66.
21. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179:76-89.
22. Depoortere R., Auclair A.L., Bardin L., Colpaert F.C., Vacher B., Newman-Tancredi A. F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur. Neuropsychopharmacol. 2010, 20:641-654.
23. 1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berl). 1995, 121:1-26.
24. Dupre K.B., Ostock C.Y., Eskow Jaunarajs K.L., Button T., Savage L.M., Wolf W., Bishop C. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp. Neurol. 2011, 229:288-299.
25. Ehrt U., Larsen J.P., Aarsland D. Pain and its relationship to depression in Parkinson disease. Am. J. Geriatr. Psychiatr. 2009, 17:269-275.
26. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-DOPA-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63:610-620.
27. Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov. Disord. 2008, 23(Suppl. 3):S497-S508.
28. Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., Jones D.E., McLenachan A., Stanhope K.J., Critchley D.J., Childs K.J., Middlefell V.C., Lanfumey L., Corradetti R., Laporte A.M., Gozlan H., Hamon M., Dourish C.T. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav. Brain Res. 1996, 73:337-353.
29. Garcia-Garcia A.L., Newman-Tancredi A., Leonardo E.D. 5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology 2014, 231:623-636.
30. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., Rascol O., Russ H. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Disord. 2007, 22:179-186.
31. Goodwin G.M., DeSouza R.J., Wood A.J., Green A.R. Lithium decreases 5-HT1A and 5-HT2 receptor and alpha 2-adrenoceptor mediated function in mice. Psychopharmacology 1986, 90:482-487.
32. Haberzettl R., Bert B., Fink H., Fox M.A. Animal models of the serotonin syndrome: a systematic review. Behav. Brain Res. 2013, 256:328-345.
33. Hamik A., Oksenberg D., Fischette C., Peroutka S.J. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol. Psychiatry 1990, 28:99-109.
34. Hely M.A., Morris J.G., Reid W.G., Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-l-DOPA-responsive problems dominate at 15years. Mov. Disord. 2005, 20:190-199.
35. 1A receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia. Neuropharmacology 2015, 93:52-67.
36. Kannari K., Kurahashi K., Tomiyama M., Maeda T., Arai A., Baba M., Suda T., Matsunaga M. Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei Brain Nerve 2002, 54:133-137.
37. Koek W., Vacher B., Cosi C., Assie M.B., Patoiseau J.F., Pauwels P.J., Colpaert F.C. 5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential. Eur. J. Pharmacol. 2001, 420:103-112.
38. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. l-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J. Neurochem. 2010, 112:1465-1476.
39. Llado-Pelfort L., Assie M.B., Newman-Tancredi A., Artigas F., Celada P. In vivo electrophysiological and neurochemical effects of the selective 5-HT(1A) receptor agonist, F13640, at pre- and postsynaptic 5-HT (1A) receptors in the rat. Psychopharmacology 2012, 221:261-272.
40. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
41. Lundblad M., Vaudano E., Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J. Neurochem. 2003, 84:1398-1410.
42. Manson A., Stirpe P., Schrag A. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J. Park. Dis. 2012, 2:189-198.
43. Mignon L.J., Wolf W.A. 8-hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 2005, 16:699-703.
44. Miguelez C., Morera-Herreras T., Torrecilla M., Ruiz-Ortega J.A., Ugedo L. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. Front. Neural Circuits 2014, 8:21.
45. Munoz A., Carlsson T., Tronci E., Kirik D., Bjorklund A., Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp. Neurol. 2009, 219:298-307.
46. Murthy J.N., Pranzatelli M.R. Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: myoclonus and other serotonergic behaviors. J. Recept. Res. 1992, 12:287-297.
47. Nahimi A., Holtzermann M., Landau A.M., Simonsen M., Jakobsen S., Alstrup A.K., Vang K., Moller A., Wegener G., Gjedde A., Doudet D.J. Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning. J. Neurochem. 2012, 120:806-817.
48. Newman-Tancredi A. Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders. Neuropsychiatry 2011, 1:149-164.
49. Newman-Tancredi A., Rivet J.M., Cussac D., Touzard M., Chaput C., Marini L., Millan M.J. Comparison of hippocampal G protein activation by 5-HT1A receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedeberg's Arch. Pharmacol. 2003, 368:188-199.
50. Newman-Tancredi A., Assie M.B., Leduc N., Ormiere A.M., Danty N., Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:341-356.
51. Olanow C.W., Damier P., Goetz C.G., Mueller T., Nutt J., Rascol O., Serbanescu A., Deckers F., Russ H. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 2004, 27:58-62.
52. Olanow C.W., Kieburtz K., Rascol O., Poewe W., Schapira A.H., Emre M., Nissinen H., Leinonen M., Stocchi F., Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease I. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov. Disord. 2013, 28:1064-1071.
53. Palfreman J. Who dropped the ball on l-DOPA? A patient's lament. J. Park. Dis. 2014, 4:313-316.
54. Papathanou M., van der Laan R., Jenner P., Rose S., McCreary A.C. Levodopa infusion does not decrease the onset of abnormal involuntary movements in Parkinsonian rats. Mov. Disord. 2013, 28:1072-1079.
55. Pauwels P.J., Tardif S., Colpaert F.C., Wurch T. Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins. Biochem. Pharmacol. 2001, 61:1079-1092.
56. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, Vol 2007, Academic Press.
57. Peroutka S.J. Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol. Psychiatry 1985, 20:971-979.
58. Pilleri M., Antonini A. Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. Expert Opin. Drug Saf. 2015, 14:281-294.
59. Poletti M., De Rosa A., Bonuccelli U. Affective symptoms and cognitive functions in Parkinson's disease. J. Neurol. Sci. 2012, 317:97-102.
60. Politis M., Wu K., Loane C., Brooks D.J., Kiferle L., Turkheimer F.E., Bain P., Molloy S., Piccini P. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J. Clin. Invest. 2014, 124:1340-1349.
61. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 1978, 47:379-391.
62. Prinssen E.P., Koek W., Colpaert F.C., Kleven M.S. Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy. Behav. Pharmacol. 2000, 11:299-305.
63. Prinssen E.P., Colpaert F.C., Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur. J. Pharmacol. 2002, 453:217-221.
64. Rana A.Q., Kabir A., Jesudasan M., Siddiqui I., Khondker S. Pain in Parkinson's disease: analysis and literature review. Clin. Neurol. Neurosurg. 2013, 115:2313-2317.
65. Rutten S., Ghielen I., Vriend C., Hoogendoorn A.W., Berendse H.W., Leentjens A.F., van der Werf Y.D., Smit J.H., van den Heuvel O.A. Anxiety in Parkinson's disease: symptom dimensions and overlap with depression and autonomic failure. Parkinsonism Relat. Disord. 2015, 21:189-193.
66. Rylander D., Recchia A., Mela F., Dekundy A., Danysz W., Cenci M.A. Pharmacological modulation of glutamate transmission in a rat model of l-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330:227-235.
67. Rylander D., Iderberg H., Li Q., Dekundy A., Zhang J., Li H., Baishen R., Danysz W., Bezard E., Cenci M.A. A mGluR5 antagonist under clinical development improves l-DOPA-induced dyskinesia in Parkinsonian rats and monkeys. Neurobiol. Dis. 2010, 39:352-361.
68. Sanchez C., Asin K.E., Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol. Ther. 2015, 145C:43-57.
69. Santana N., Bortolozzi A., Serrats J., Mengod G., Artigas F. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 2004, 14:1100-1109.
70. Svenningsson P., Rosenblad C., Af Edholm Arvidsson K., Wictorin K., Keywood C., Shankar B., Lowe D.A., Bjorklund A., Widner H. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain J. Neurol. 2015, 138:963-973.
71. Tambasco N., Simoni S., Marsili E., Sacchini E., Murasecco D., Cardaioli G., Rossi A., Calabresi P. Clinical aspects and management of levodopa-induced dyskinesia. Park. Dis. 2012, 2012:745947.
72. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10:631-634.
73. van Amsterdam C., Seyfried C.A. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output. Psychopharmacology 2014, 231:2547-2558.
74. 18F]F13640, a novel 5-HT1A receptor agonist. J. Nucl. Med. 2014, 55:1100.
75. Westin J.E., Lindgren H.S., Gardi J., Nyengaard J.R., Brundin P., Mohapel P., Cenci M.A. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-l-alanine-induced dyskinesia. J. Neurosci. Off. J. Soc. Neurosci. 2006, 26:9448-9461.
76. Winkler C., Kirik D., Bjorklund A., Cenci M.A. l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.